SBIR/STTR Research Award

A Non-Invasive Method to Distinguish Melanomas from Benign Skin Lesions

Award identifier 758f3cd03a8df2b707d7fc3f707c9b908bb1c34613b414ddd24be698dab5784aAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,000

Program and phase

SBIR · Phase I

Award year

2008

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
DERMATEX, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2007-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): In this Phase I SBIR project, we shall show the feasibility of a unique, patent pending method to differentiate benign lesions such as moles (benign and dysplastic nevi) or liver spots (lentigenes solaris), from maligna nt ones, such as lentigenes maligna and melanoma. Melanoma is a deadly cancer for which early diagnosis is key to survival. Our goal is to describe the surface textures of melanomas and benign lesions that simulate melanomas to show the feasibility for the development of a low cost, non-invasive, and objective aid in melanoma diagnosis. Preliminary data show that skin texture differs between non-cancerous lesions (benign moles, atypical moles, and liver spots), and malignant lesions (melanoma in situ and in vasive melanoma). The Phase I project will refine measurement and analysis protocols to develop practical applicable standards sufficient to describe texture differences across lesion types. It will demonstrate feasibility of the patent pending surface tex ture analysis techniques by showing statistically significant differences in texture for invasive melanomas. Narrative Melanoma is among the deadliest of cancers and can be difficult to diagnose in a clinical setting without excision and subsequent histolo gical analysis. If surface texture can distinguish benign neoplasms of the skin from melanoma, a low cost, rapid, non-invasive diagnostic tool may be developed to facilitate early detection and thereby save lives.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.